Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atrion Co. stock logo
ATRI
Atrion
$424.19
+4.7%
$402.59
$274.98
$643.48
$746.57M0.617,697 shs20,753 shs
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
$31.20
+1.9%
$28.26
$23.10
$53.50
$728.57M1.16182,206 shs83,481 shs
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
$10.09
$10.09
$9.68
$10.15
N/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
$12.53
-2.0%
$14.16
$11.98
$34.86
$469.15M0.89476,396 shs514,963 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atrion Co. stock logo
ATRI
Atrion
+4.66%+6.38%-2.93%+30.73%-34.08%
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
+1.86%+4.35%+19.04%+17.12%-36.93%
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
0.00%0.00%0.00%0.00%0.00%
Nevro Corp. stock logo
NVRO
Nevro
-2.19%+1.95%-8.21%-30.66%-61.71%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atrion Co. stock logo
ATRI
Atrion
1.5127 of 5 stars
0.01.02.50.02.23.31.3
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
3.6699 of 5 stars
3.41.00.03.90.64.20.6
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
N/AN/AN/AN/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
1.3195 of 5 stars
4.01.00.00.00.01.70.6

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atrion Co. stock logo
ATRI
Atrion
N/AN/AN/AN/A
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
2.75
Moderate Buy$42.5036.22% Upside
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
N/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
2.00
Hold$21.2369.44% Upside

Current Analyst Ratings

Latest KIDS, LGV, ATRI, and NVRO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/15/2024
Nevro Corp. stock logo
NVRO
Nevro
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetSector Perform ➝ Sector Perform$18.00 ➝ $16.00
4/11/2024
Nevro Corp. stock logo
NVRO
Nevro
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$20.00 ➝ $16.00
4/10/2024
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$37.00
4/8/2024
Nevro Corp. stock logo
NVRO
Nevro
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$17.00 ➝ $14.00
4/3/2024
Nevro Corp. stock logo
NVRO
Nevro
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$18.00 ➝ $16.00
3/7/2024
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$50.00
2/22/2024
Nevro Corp. stock logo
NVRO
Nevro
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$23.00 ➝ $19.00
2/22/2024
Nevro Corp. stock logo
NVRO
Nevro
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$20.00 ➝ $17.00
2/22/2024
Nevro Corp. stock logo
NVRO
Nevro
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOutperform ➝ Market Perform
1/25/2024
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$39.00 ➝ $31.00
(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atrion Co. stock logo
ATRI
Atrion
$169.33M4.41$20.80 per share20.39$138.02 per share3.07
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
$148.73M4.99N/AN/A$16.14 per share1.93
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
N/AN/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
$425.17M1.08N/AN/A$8.10 per share1.55

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atrion Co. stock logo
ATRI
Atrion
$19.41M$11.0338.46N/A11.46%8.07%7.37%5/13/2024 (Estimated)
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
-$20.97M-$0.92N/AN/AN/A-14.10%-5.03%-4.37%5/6/2024 (Confirmed)
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
$7.40MN/A0.00N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
-$92.21M-$2.57N/AN/AN/A-21.69%-30.22%-15.17%5/7/2024 (Confirmed)

Latest KIDS, LGV, ATRI, and NVRO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/7/2024N/A
Nevro Corp. stock logo
NVRO
Nevro
-$1.02N/A+$1.02N/AN/AN/A  
5/6/2024N/A
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
-$0.42N/A+$0.42N/AN/AN/A  
3/6/2024Q4 2023
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
-$0.28-$0.23+$0.05-$0.17$37.59 million$37.61 million
2/29/2024Q4 2023
Atrion Co. stock logo
ATRI
Atrion
N/A$3.65+$3.65$3.65N/A$43.58 million
2/21/2024Q4 2023
Nevro Corp. stock logo
NVRO
Nevro
-$0.50-$0.15+$0.35-$0.05$115.93 million$116.18 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atrion Co. stock logo
ATRI
Atrion
$8.802.07%+9.65%79.78%21 Years
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
N/AN/AN/AN/AN/A
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
N/AN/AN/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
N/AN/AN/AN/AN/A

Latest KIDS, LGV, ATRI, and NVRO Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/27/2024
Atrion Co. stock logo
ATRI
Atrion
Quarterly$2.202.42%3/14/20243/15/20243/29/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atrion Co. stock logo
ATRI
Atrion
N/A
9.09
2.57
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
0.03
5.44
2.90
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
N/AN/AN/A
Nevro Corp. stock logo
NVRO
Nevro
0.72
6.37
4.94

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Atrion Co. stock logo
ATRI
Atrion
66.19%
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
69.05%
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
N/A
Nevro Corp. stock logo
NVRO
Nevro
95.52%

Insider Ownership

CompanyInsider Ownership
Atrion Co. stock logo
ATRI
Atrion
22.70%
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
31.80%
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
26.35%
Nevro Corp. stock logo
NVRO
Nevro
3.20%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Atrion Co. stock logo
ATRI
Atrion
7121.76 million1.36 millionNot Optionable
OrthoPediatrics Corp. stock logo
KIDS
OrthoPediatrics
24723.79 million16.22 millionOptionable
Longview Acquisition Corp. II stock logo
LGV
Longview Acquisition Corp. II
3N/AN/ANot Optionable
Nevro Corp. stock logo
NVRO
Nevro
1,21536.68 million35.51 millionOptionable

KIDS, LGV, ATRI, and NVRO Headlines

SourceHeadline
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
finance.yahoo.com - April 17 at 10:38 AM
Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024Nevro to Report First-Quarter 2024 Financial Results and Host Earnings Conference Call on May 7, 2024
prnewswire.com - April 17 at 8:30 AM
Nevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of CanadaNevro (NYSE:NVRO) Given New $16.00 Price Target at Royal Bank of Canada
americanbankingnews.com - April 16 at 3:44 AM
Nevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of CanadaNevro (NYSE:NVRO) Price Target Lowered to $16.00 at Royal Bank of Canada
marketbeat.com - April 15 at 3:31 PM
Nevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by AnalystsNevro Corp. (NYSE:NVRO) Given Average Rating of "Hold" by Analysts
marketbeat.com - April 12 at 2:33 AM
Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00Mizuho Cuts Nevro (NYSE:NVRO) Price Target to $16.00
marketbeat.com - April 11 at 8:25 AM
Nevro (NYSE:NVRO) Trading Up 5.5%Nevro (NYSE:NVRO) Trading Up 5.5%
marketbeat.com - April 9 at 12:12 PM
Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)Assenagon Asset Management S.A. Lowers Stock Holdings in Nevro Corp. (NYSE:NVRO)
marketbeat.com - April 5 at 4:35 AM
Where Nevro Stands With AnalystsWhere Nevro Stands With Analysts
benzinga.com - April 3 at 1:52 PM
Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00Citigroup Trims Nevro (NYSE:NVRO) Target Price to $16.00
marketbeat.com - April 3 at 12:14 PM
Nevro (NYSE:NVRO) Stock Price Down 4.8%Nevro (NYSE:NVRO) Stock Price Down 4.8%
marketbeat.com - April 1 at 2:58 PM
EnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology CommercializationEnviroGold Global Limited: NVRO announces Management Changes and provides an update on its Proprietary Leaching Technology Commercialization
finanznachrichten.de - March 25 at 4:30 PM
Heres Why You Should Retain Nevro (NVRO) Stock for NowHere's Why You Should Retain Nevro (NVRO) Stock for Now
zacks.com - March 21 at 1:36 PM
NVRO Mar 2024 20.000 putNVRO Mar 2024 20.000 put
finance.yahoo.com - March 11 at 12:27 AM
Nevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral ScrewNevro (NVRO) Gets FDA Nod for SI Fixation Without Lateral Screw
zacks.com - February 29 at 8:31 AM
Nevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral ScrewNevro Receives FDA 510(k) Clearance to Use SI Fixation System Without Need to Include Lateral Screw
prnewswire.com - February 28 at 4:10 PM
Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)Analysts Offer Insights on Healthcare Companies: Nevro Corp (NVRO), Karuna Therapeutics (KRTX) and Gilead Sciences (GILD)
markets.businessinsider.com - February 27 at 1:07 AM
Nevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market UncertaintyNevro Corp: Hold Rating Affirmed Amidst Mixed Performance and Market Uncertainty
markets.businessinsider.com - February 26 at 7:38 AM
Nevro just downgraded at Oppenheimer, heres whyNevro just downgraded at Oppenheimer, here's why
realmoney.thestreet.com - February 23 at 2:42 AM
Nevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial ResultsNevro Corp.: Nevro Reports Fourth-Quarter and Full-Year 2023 Financial Results
finanznachrichten.de - February 22 at 9:41 PM
Why Nevro Stock Lagged the Market on ThursdayWhy Nevro Stock Lagged the Market on Thursday
fool.com - February 22 at 6:21 PM
Hold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 OutlookHold Rating on Nevro Corp Amid Modest Growth and Cautious 2024 Outlook
markets.businessinsider.com - February 22 at 2:16 PM
Analyst Scoreboard: 4 Ratings For NevroAnalyst Scoreboard: 4 Ratings For Nevro
markets.businessinsider.com - February 22 at 2:16 PM
Nevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call TranscriptNevro Corp. (NYSE:NVRO) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 22 at 2:16 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Atrion logo

Atrion

NASDAQ:ATRI
Atrion Corporation, together with its subsidiaries, develops, manufactures, and sells products for fluid delivery, cardiovascular, and ophthalmic applications in the United States, Canada, Europe, and internationally. The company's fluid delivery products include valves that fill, hold, and release controlled amounts of fluids or gasses for use in various intubation, intravenous, catheter, and other applications in the anesthesia and oncology fields, as well as promote infection control in hospital and home healthcare environments. Its cardiovascular products comprise Myocardial Protection System that delivers fluids and medications, and mixes critical drugs, as well as controls temperature, pressure, and other variables; cardiac surgery vacuum relief valves; silicone vessel loops for retracting and occluding vessels; and inflation devices for balloon catheter dilation, stent deployment, and fluid dispensing, as well as products for use in heart bypass surgery. The company's ophthalmic products consist of a line of balloon catheters, which are used for the treatment of nasolacrimal duct obstruction in children and adults. It manufactures products for safe needle and scalpel blade containment; inflation systems and valves used in marine and aviation safety products; components used in inflatable survival products and structures; and one-way and two-way pressure relief valves that protect sensitive electronics and other products during transport in other medical and non-medical applications. The company sells its products to physicians, hospitals, clinics, and other treatment centers; and other equipment manufacturers through direct sales force, independent sales representatives, and distributors. Atrion Corporation was founded in 1944 and is headquartered in Allen, Texas.
OrthoPediatrics logo

OrthoPediatrics

NASDAQ:KIDS
OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.
Longview Acquisition Corp. II logo

Longview Acquisition Corp. II

NYSE:LGV
Longview Acquisition Corp. II does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company intends to focus on businesses in the healthcare, industrials, consumer, media, technology, and technology services sector. The company was incorporated in 2020 and is based in New York, New York.
Nevro logo

Nevro

NYSE:NVRO
Nevro Corp., a medical device company, engages in the provision of products for patients suffering from chronic pain in the United States and internationally. The company provides HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS implantable pulse generator (IPG) system, an evidence-based neuromodulation system for the treatment of chronic back and leg pain through paresthesia-free 10 kHz therapy, as well as offers Senza II and Senza Omnia SCS IPG systems. It also offers Senza HFX iQ platform, that includes HFX iQ implantable pulse generator, HFX trial stimulator, and HFX iQ patient remote, as well as HFX App, a patient remote control and the wireless trialing system; and provides sacroiliac joint fusion devices under NevroV1, NevroFix, and NevroPro brands. In addition, the company offers surpass surgical and percutaneous leads. It sells its products through its direct sales force, and a network of sales agents and independent distributors. The company was incorporated in 2006 and is headquartered in Redwood City, California.